Comparison of the effect of general and spinal anesthesia on serum level and gene expression of interleukin 4, 6, 10 and 17; TGF-β and IFN-γ in maternal and umbelical cord blood in elective cesarean section
Red color represents old content. It may be empty showing addition in the new version.
Green color represents new content. It may be empty showing deletion in the new version.
Inline
Side by side
Added new contents,
deleted old contents,contents that are not changed.
New table contents
New table contents
Old table contents
Old table contents
Unchanged contents
Unchanged contents
Added new contents, contents that are not changed.
Deleted old contents, contents that are not changed.
Old table contents
Old table contents
Unchanged contents
Unchanged contents
New table contents
New table contents
Unchanged contents
Unchanged contents
Protocol summary
After entering women who are candidate for cesarean section referred to Niknafs Hospital in Rafsanjan, An anesthesiologist will visit the patients. If there is no contraindication for spinal or general anesthesia and none of the methods is preferred for the patient, the anesthesiologist will tell the patient about the research project.If the patient agrees to participate in the study, he will sign an informed consent form. Person who tests interleukin-assays, extracts RNA and synthesizes cDNA is blinded to the study groups.
After entering women who are candidate for cesarean referred to Niknafs Hospital in Rafsanjan, An anesthesiologist will visit the patients. If there is no contraindication for SA or GA and none of the methods is preferred for the patient, the anesthesiologist will tell the patient about the research project. If the patient agrees to participate in the study, he will sign an informed consent form. Person who tests interleukin-assays, extracts RNA and synthesizes cDNA is blinded to the study groups.
After entering women who are candidate for cesarean section referred to Niknafs Hospital in Rafsanjan, An anesthesiologist will visit the patients. If there is no contraindication for spinalSA or general anesthesiaGA and none of the methods is preferred for the patient, the anesthesiologist will tell the patient about the research project.Ifproject. If the patient agrees to participate in the study, he will sign an informed consent form. Person who tests interleukin-assays, extracts RNA and synthesizes cDNA is blinded to the study groups.
پس از ورود زنان کاندید عمل جراحی سزارین مراجعه کننده به بیمارستان نیک نفس رفسنجان، متخصص بیهوشی بیمار را مورد معاینه قرار میدهد در صورتی که کنتراندیکاسیونی برای انجام بیحسی نخاعی یا بیهوشی عمومی وجود نداشته باشد و هیچیک از روشهای بیحسی نخاعی با بیهوشی عمومی برای بیمار ارجحیت نداشته باشد، متخصص بیهوشی در مورد طرح پژوهشی توضیحات لازم را به بیمار میدهد و در صورت موافقت بیمار برای شرکت در مطالعه، فرم رضایت آگاهانه در اختیار وی قرار داده میشود. فردی که آزمایشات سنجش اینترلوکینها، استخراج RNA و سنتز cDNA را انجام میدهد از گروه بندی بیماران اطلاعی ندارد
پس از ورود زنان کاندید عمل سزارین به بیمارستان نیک نفس رفسنجان، متخصص بیهوشی بیمار را مورد معاینه قرار میدهد در صورتی که کنتراندیکاسیونی برای انجام بیحسی نخاعی یا بیهوشی عمومی وجود نداشته باشد و هیچیک از روشها برای بیمار ارجحیت نداشته باشد، متخصص بیهوشی توضیحات لازم را میدهد و در صورت موافقت بیمار ، فرم رضایت آگاهانه در اختیار وی قرار داده میشود. فردی که آزمایشات سنجش اینترلوکینها، استخراج RNA و سنتز cDNA را انجام میدهد از گروه بندی بیماران اطلاعی ندارد
پس از ورود زنان کاندید عمل جراحی سزارین مراجعه کننده به بیمارستان نیک نفس رفسنجان، متخصص بیهوشی بیمار را مورد معاینه قرار میدهد در صورتی که کنتراندیکاسیونی برای انجام بیحسی نخاعی یا بیهوشی عمومی وجود نداشته باشد و هیچیک از روشهای بیحسی نخاعی با بیهوشی عمومیروشها برای بیمار ارجحیت نداشته باشد، متخصص بیهوشی در مورد طرح پژوهشی توضیحات لازم را به بیمار میدهد و در صورت موافقت بیمار برای شرکت در مطالعه، فرم رضایت آگاهانه در اختیار وی قرار داده میشود. فردی که آزمایشات سنجش اینترلوکینها، استخراج RNA و سنتز cDNA را انجام میدهد از گروه بندی بیماران اطلاعی ندارد
Inclusion criteria: having reading and writing skill, being at the age of 20 to 45, single pregnancy, term pregnancy and no complications such as chorioamnionitis and premature rupture of membrane. Exclusion criteria: unwanted pregnancy, a history of illness such as hypertension, diabetes, Cardiovascular disease, history of immunodeficiency diseases including HIV and hepatitis B, mental disorders, inflammatory diseases, drug use, smoking, alcohol and opium addiction
Inclusion criteria: age 20 to 45, single pregnancy, term pregnancy and no complications such as chorioamnionitis and premature rupture of membrane. Exclusion criteria: unwanted pregnancy, a history of illness such as hypertension, diabetes, Cardiovascular disease, history of immunodeficiency diseases including HIV and hepatitis B, mental disorders, inflammatory diseases, drug use, smoking, alcohol and opium addiction
Inclusion criteria: having reading and writing skill, being at the age of 20 to 45, single pregnancy, term pregnancy and no complications such as chorioamnionitis and premature rupture of membrane. Exclusion criteria: unwanted pregnancy, a history of illness such as hypertension, diabetes, Cardiovascular disease, history of immunodeficiency diseases including HIV and hepatitis B, mental disorders, inflammatory diseases, drug use, smoking, alcohol and opium addiction
معیارهای ورود عبارتند از داشتن سواد خواندن و نوشتن، سن 20 تا 45 سال، حاملگی تک قلو، حاملگي ترم و بـدون عوارضـي هـمچـون كوريوآمينونيـت و پارگی زودرس کیسه آب و معیارهای خروج از مطالعه شامل: حاملگی ناخواسته، سـابقه بيمـاري زمينـه اي از قبيـل افزایش فشـارخون، ديابت، بيماري قلبي- عروقـي، سابقه بیماریهای نقص ایمنی شامل HIV و هپاتیت B، اختلالات روانی، بیماریهای التهابی، مصـرف دارو، سـيگار، الكـل و اعتيـاد بـه مـواد مخدر
معیارهای ورود سن 20 تا 45 سال، حاملگی تک قلو، حاملگي ترم و بـدون عوارضـي هـمچـون كوريوآمينونيـت و پارگی زودرس کیسه آب و معیارهای خروج شامل: حاملگی ناخواسته، سـابقه بيمـاري زمينـه اي از قبيـل افزایش فشـارخون، ديابت، بيماري قلبي- عروقـي، سابقه بیماریهای نقص ایمنی شامل HIV و هپاتیت B، اختلالات روانی، بیماریهای التهابی، مصـرف دارو، سـيگار، الكـل و اعتيـاد بـه مـواد مخدر
معیارهای ورود عبارتند از داشتن سواد خواندن و نوشتن، سن 20 تا 45 سال، حاملگی تک قلو، حاملگي ترم و بـدون عوارضـي هـمچـون كوريوآمينونيـت و پارگی زودرس کیسه آب و معیارهای خروج از مطالعه شامل: حاملگی ناخواسته، سـابقه بيمـاري زمينـه اي از قبيـل افزایش فشـارخون، ديابت، بيماري قلبي- عروقـي، سابقه بیماریهای نقص ایمنی شامل HIV و هپاتیت B، اختلالات روانی، بیماریهای التهابی، مصـرف دارو، سـيگار، الكـل و اعتيـاد بـه مـواد مخدر
Intervention group 1 (general anesthesia group): In this group induction of general anesthesia will be performed using thiopental, 4-6 mg / kg sodium and succinylcholine, 1-1.5 mg /kg.
Intervention group 2 (spinal anesthesia group): spinal anesthesia will be performd through injection of 0.5 ml marcaine (0.5% produced by AstraZeneca, Sweden) in the sub-arachnoid space using a quincke needle (produced in Japan), at the L3-L4 level in the sitting position.
Intervention group 1 (GA group): In this group induction of anesthesia will be performed using thiopental, 4-6 mg / kg sodium and succinylcholine, 1-1.5 mg /kg.
Intervention group 2 (SA): spinal anesthesia will be performd through injection of 0.5 ml marcaine (0.5% produced by AstraZeneca, Sweden) in the sub-arachnoid space using a quincke needle (produced in Japan), at the L3-L4 level in the sitting position.
Intervention group 1 (general anesthesiaGA group): In this group induction of general anesthesia will be performed using thiopental, 4-6 mg / kg sodium and succinylcholine, 1-1.5 mg /kg. Intervention group 2 (spinal anesthesia groupSA): spinal anesthesia will be performd through injection of 0.5 ml marcaine (0.5% produced by AstraZeneca, Sweden) in the sub-arachnoid space using a quincke needle (produced in Japan), at the L3-L4 level in the sitting position.
گروه مداخله 1 (گروه بیهوشی عمومی): در این گروه القای بیهوشی عمومی با استفاده از 6- 4 میلیگرم بر کیلوگرم سدیم تیوپنتال و 5/1-1 میلیگرم بر کیلوگرم سوکسینیل کولین انجام میشود.
گروه مداخله 2 (گروه بیحسی نخاعی): بیحسی نخاعی در پوزیشن نشسته با استفاده از سوزن اسپینال شماره 25 (quincke needle، ساخت ژاپن) و تزریق 2/5 میلی لیتر مارکائین 0/5% (ساخت شرکت AstraZeneca سوئد) در فضای ساب آراکنوئید در سطح L3-L4 انجام میشود.
گروه مداخله 1 (گروه بیهوشی عمومی): در این گروه القای بیهوشی با استفاده از 6- 4 میلیگرم بر کیلوگرم سدیم تیوپنتال و 5/1-1 میلیگرم بر کیلوگرم سوکسینیل کولین انجام میشود.
گروه مداخله 2 (گروه بیحسی نخاعی): بیحسی نخاعی در پوزیشن نشسته با استفاده از سوزن اسپینال شماره 25 (quincke needle، ساخت ژاپن) و تزریق 2/5 میلی لیتر مارکائین 0/5% (ساخت شرکت AstraZeneca سوئد) در فضای ساب آراکنوئید در سطح L3-L4 انجام میشود.
گروه مداخله 1 (گروه بیهوشی عمومی): در این گروه القای بیهوشی عمومی با استفاده از 6- 4 میلیگرم بر کیلوگرم سدیم تیوپنتال و 5/1-1 میلیگرم بر کیلوگرم سوکسینیل کولین انجام میشود. گروه مداخله 2 (گروه بیحسی نخاعی): بیحسی نخاعی در پوزیشن نشسته با استفاده از سوزن اسپینال شماره 25 (quincke needle، ساخت ژاپن) و تزریق 2/5 میلی لیتر مارکائین 0/5% (ساخت شرکت AstraZeneca سوئد) در فضای ساب آراکنوئید در سطح L3-L4 انجام میشود.
General information
empty
40
40
empty
2018-04-21, 1397/02/01
2018-04-21 00:00:00
empty
2018-06-22, 1397/04/01
2018-06-22 00:00:00
empty
2018-06-23, 1397/04/02
2018-06-23 00:00:00
Sponsors / Funding sources
#1
Name of organization / entity - English:
Name of organization / entity - Persian:
Full name of responsible person - English: Ali Shamsy zadeh
Full name of responsible person - Persian: علی شمسی زاده
Street address - English: Rafsanjan University of medical Sciences
Street address - Persian: خیابان شهدا
City - English: Rafsanjan
City - Persian: رفسنجان
Province: Kerman
Country: Iran (Islamic Republic of)
Postal code: 7716913411
Phone: +98 34 3425 8397
Fax:
Email: hadavi1344@rums.ac.ir
Web page address:
Name of organization / entity - English:
Name of organization / entity - Persian:
Full name of responsible person - English: Ali Shamsyzadeh
Full name of responsible person - Persian: علی شمسی زاده
Street address - English: Rafsanjan University of Medical Sciences
Street address - Persian: خیابان شهدا
City - English: Rafsanjan
City - Persian: رفسنجان
Province: Kerman
Country: Iran (Islamic Republic of)
Postal code: 7716913411
Phone: +98 34 3425 8397
Fax:
Email: hadavi1344@rums.ac.ir
Web page address:
Name of organization / entity - English: Name of organization / entity - Persian: Full name of responsible person - English: Ali Shamsy zadehShamsyzadeh Full name of responsible person - Persian: علی شمسی زاده Street address - English: Rafsanjan University of medicalMedical Sciences Street address - Persian: خیابان شهدا City - English: Rafsanjan City - Persian: رفسنجان Province: Kerman Country: Iran (Islamic Republic of) Postal code: 7716913411 Phone: +98 34 3425 8397 Fax: Email: hadavi1344@rums.ac.ir Web page address:
Protocol summary
Study aim
Determining the effect of general and spinal anesthesia on serum level and gene expression of IL 4, 6, 10, 17, TGF-β and IFN-γ in maternal and umbilical cord blood in elective cesarean section
Design
Clinical trial with 2 parallel groups, single blind, randomised, 20 patients in each group
Settings and conduct
After entering women who are candidate for cesarean referred to Niknafs Hospital in Rafsanjan, An anesthesiologist will visit the patients. If there is no contraindication for SA or GA and none of the methods is preferred for the patient, the anesthesiologist will tell the patient about the research project. If the patient agrees to participate in the study, he will sign an informed consent form. Person who tests interleukin-assays, extracts RNA and synthesizes cDNA is blinded to the study groups.
Participants/Inclusion and exclusion criteria
Inclusion criteria: age 20 to 45, single pregnancy, term pregnancy and no complications such as chorioamnionitis and premature rupture of membrane. Exclusion criteria: unwanted pregnancy, a history of illness such as hypertension, diabetes, Cardiovascular disease, history of immunodeficiency diseases including HIV and hepatitis B, mental disorders, inflammatory diseases, drug use, smoking, alcohol and opium addiction
Intervention groups
Intervention group 1 (GA group): In this group induction of anesthesia will be performed using thiopental, 4-6 mg / kg sodium and succinylcholine, 1-1.5 mg /kg.
Intervention group 2 (SA): spinal anesthesia will be performd through injection of 0.5 ml marcaine (0.5% produced by AstraZeneca, Sweden) in the sub-arachnoid space using a quincke needle (produced in Japan), at the L3-L4 level in the sitting position.
Main outcome variables
mean and standard deviation of serum levels and gene expression of interleukins 4, 6, 10 and 17; TGF-β and IFN-γ in maternal and umbilical cord blood
General information
Reason for update
Acronym
IRCT registration information
IRCT registration number:IRCT20180304038943N1
Registration date:2018-04-17, 1397/01/28
Registration timing:prospective
Last update:2018-11-05, 1397/08/14
Update count:1
Registration date
2018-04-17, 1397/01/28
Registrant information
Name
maryam Hadavi
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 34 3425 8397
Email address
hadavi1344@rums.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2018-03-17, 1396/12/26
Expected recruitment end date
2018-04-09, 1397/01/20
Actual recruitment start date
2018-04-21, 1397/02/01
Actual recruitment end date
2018-06-22, 1397/04/01
Trial completion date
2018-06-23, 1397/04/02
Scientific title
Comparison of the effect of general and spinal anesthesia on serum level and gene expression of interleukin 4, 6, 10 and 17; TGF-β and IFN-γ in maternal and umbelical cord blood in elective cesarean section
Public title
The anesthesia effect on serum levels and gene expression of interleukins in elective cesarean section
Purpose
Basic scienece
Inclusion/Exclusion criteria
Inclusion criteria:
Having reading and writing skills
being at the age of 20 to 45 years
single pregnancy
term pregnancy without complications such as Corioamnionitis and preterm rupture of membrane
Exclusion criteria:
Unwanted pregnancy
History of underlying illness including hypertension, diabetes, cardiovascular disease
History of immunodeficiency diseases including HIV and hepatitis B
mental disorders
Inflammatory diseases
History of drug abuse, smoking, Opium addiction
Age
From 20 years old to 45 years old
Gender
Female
Phase
N/A
Groups that have been masked
Outcome assessor
Sample size
Target sample size:
40
Actual sample size reached:
40
Randomization (investigator's opinion)
Randomized
Randomization description
Patients will be randomly assigned to General or spinal anesthesia groups using sealed envelopes (40 sealed envelopes, 20 of which were marked with G = general anesthesia and 20 with the sign S = spinal anesthesia).
Blinding (investigator's opinion)
Single blinded
Blinding description
The person who will perform tests to measure interleukins, extract RNA and synthesize cDNA will be kept blind to the study groups.
Placebo
Not used
Assignment
Parallel
Other design features
Secondary Ids
empty
Ethics committees
1
Ethics committee
Name of ethics committee
Ethics committee of Rafsanjan University of Medical Sciences
Street address
Molecular Medicine Research Center, Medical School, Khalije Fars Blvd., Pesteh Blvd.
City
Rafsanjan
Province
Kerman
Postal code
7716913411
Approval date
2017-01-09, 1395/10/20
Ethics committee reference number
IR.RUMS.REC.1395.125
Health conditions studied
1
Description of health condition studied
The effect of anesthesia technique on the immune system
ICD-10 code
ICD-10 code description
Primary outcomes
1
Description
serum level of interleukin 4 in maternal blood before and after intervention
Timepoint
Measurement of serum level of IL-4 before study, after uterine incision, 2 hours after surgery, 24 hours after surgery
Method of measurement
ELISA test, Real Time PCR method
2
Description
serum level of interleukin 6 in maternal blood before and after intervention
Timepoint
Measurement of serum level of IL-6 before study, after uterine incision, 2 hours after surgery, 24 hours after surgery
Method of measurement
ELISA test, Real Time PCR method
3
Description
serum level of interleukin 10 in maternal blood before and after intervention
Timepoint
Measurement of serum level of IL-10 before study, after uterine incision, 2 hours after surgery, 24 hours after surgery
Method of measurement
ELISA test, Real Time PCR method
4
Description
serum level of interleukin 17 in maternal blood before and after intervention
Timepoint
Measurement of serum level of IL-17 before study, after uterine incision, 2 hours after surgery, 24 hours after surgery
Method of measurement
ELISA test, Real Time PCR method
5
Description
serum level of interleukin IFN-γ in maternal blood before and after intervention
Timepoint
Measurement of serum level of IFN-γ before study, after uterine incision, 2 hours after surgery, 24 hours after surgery
Method of measurement
ELISA test, Real Time PCR method
6
Description
serum level of interleukin TGF-β in maternal blood before and after intervention
Timepoint
Measurement of serum level of TGF-β before study, after uterine incision, 2 hours after surgery, 24 hours after surgery
Method of measurement
ELISA test, Real Time PCR method
7
Description
Serum level of interleukin 4 in the umbilical cord blood of the baby
Timepoint
Immediately after birth
Method of measurement
Elisa test, Real Time PCR method
8
Description
Serum level of interleukin 6 in the umbilical cord blood of the baby
Timepoint
Immediately after birth
Method of measurement
ELISA test, Real Time PCR method
9
Description
Serum level of interleukin 10 in the umbilical cord blood of the baby
Timepoint
Immediately after birth
Method of measurement
ELISA test, Real Time PCR method
10
Description
Serum level of interleukin 17 in the umbilical cord blood of the baby
Timepoint
Immediately after birth
Method of measurement
ELISA test, Real Time PCR method
11
Description
Serum level of IFN-γ in the umbilical cord blood of the baby
Timepoint
Immediately after birth
Method of measurement
ELISA test, Real Time PCR method
12
Description
Serum level of TGF-β in the umbilical cord blood of the baby
Timepoint
Immediately after birth
Method of measurement
ELISA test, Real Time PCR method
Secondary outcomes
1
Description
post operative pain
Timepoint
6, 12 and 24 hours after surgery
Method of measurement
Visual Analog Scale (VAS)
Intervention groups
1
Description
Intervention group 1 (general anesthesia group): In this group, after controlling the vital signs and administration of 100% oxygen using a mask and a pulse oximeter, induction of general anesthesia will be performed using thiopental, 4-6 mg / kg sodium and succinylcholine, 1-1.5 mg /kg. After tracheal intubation with Tube No. 7, oxygen and nitrous oxide are administered (50%). During the surgery Muscle relaxation will be performed using atracurium, 0.2-0.3 mg / kg.
Category
N/A
2
Description
Intervention group 2 (spinal anesthesia group): After controlling the vital signs, connecting the pulse oximeter's probe and starting the infusion of fluid, spinal anesthesia will be performd through injection of 0.5 ml marcaine (0.5% produced by AstraZeneca, Sweden) in the sub-arachnoid space using a quincke needle (produced in Japan), at the L3-L4 level in the sitting position. After administering the drug to the subarachnoid space, the patient will be placed immediately in the supine position.
Category
N/A
Recruitment centers
1
Recruitment center
Name of recruitment center
Niknafs hospital
Full name of responsible person
Maryam Hadavi
Street address
Shohada Street
City
Rafsanjan
Province
Kerman
Postal code
7716913411
Phone
+98 34 3425 8397
Email
hadavi1344@ruma.ac.ir
Sponsors / Funding sources
1
Sponsor
Name of organization / entity
Rafsanjan University of Medical Sciences
Full name of responsible person
Ali Shamsyzadeh
Street address
Rafsanjan University of Medical Sciences
City
Rafsanjan
Province
Kerman
Postal code
7716913411
Phone
+98 34 3425 8397
Email
hadavi1344@rums.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Rafsanjan University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic
Person responsible for general inquiries
Contact
Name of organization / entity
Rafsanjan University of Medical Sciences
Full name of responsible person
maryam hadavi
Position
Instructor
Latest degree
Master
Other areas of specialty/work
Anesthesiology
Street address
Imam Ali Boulevard
City
Rafsanjan
Province
Kerman
Postal code
7716913411
Phone
+98 34280038
Email
hadavi1344@rums.ac.ir
Person responsible for scientific inquiries
Contact
Name of organization / entity
Rafsanjan University of Medical Sciences
Full name of responsible person
maryam hadavi
Position
Instructor
Latest degree
Master
Other areas of specialty/work
Anesthesiology
Street address
Imam Ali Boulevard
City
Rafsanjan
Province
Kerman
Postal code
7716913411
Phone
+98 34 3425 8397
Email
hadavi1344@rums.ac.ir
Person responsible for updating data
Contact
Name of organization / entity
Rafsanjan University of Medical Sciences
Full name of responsible person
maryam hadavi
Position
Instructor
Latest degree
Master
Other areas of specialty/work
Anesthesiology
Street address
Rafsanjan University of Medical Sciences, Imam Ali Boulevard
City
Rafsanjan
Province
Kerman
Postal code
7716913411
Phone
+98 34 3425 0038
Email
hadavi1344@rums.ac.ir
Sharing plan
Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
No - There is not a plan to make this available
Statistical Analysis Plan
No - There is not a plan to make this available
Informed Consent Form
No - There is not a plan to make this available
Clinical Study Report
No - There is not a plan to make this available
Analytic Code
No - There is not a plan to make this available
Data Dictionary
No - There is not a plan to make this available
Title and more details about the data/document
The gene expression, mean distribution and the standard deviation of interleukin in the two groups will share. Data will share without the attendee names.
When the data will become available and for how long
One year after publishing the results
To whom data/document is available
people working in academic institutions
Under which criteria data/document could be used
Research centers
From where data/document is obtainable
hadavimaryam@yahoo.com
What processes are involved for a request to access data/document
Sending an email to the responsible author, after the qualification of the applicant for a maximum of two months